TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01971164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951
Description: Subjects will receive JTZ-951 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951
Description: Subjects will receive JTZ-951 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951
Description: Subjects will receive JTZ-951 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00544115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study: NCT04710927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: A single application of SDF 38% (Riva Star) on dry affected molar for 1 minute and immediately restored using HVGIC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Papain-Based Gel
Description: Papain based Gel (Papacare Duo) will be applied to the MIH affected molar for 60 seconds and repeated if required. The molar will be treated with SDF and restored using HVGIC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Viscosity Glass Ionomer Cement (HVGIC)
Description: The molar will be restored with HVGIC
Study: NCT00330915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days x 3 cycles
Study: NCT01702441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous AKB-9778
Study: NCT03651102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide and Hydroxyurea
Description: Dosage: Thalidomide 1-4mg/kg/day, Hydroxyurea 10-20mg/kg/day
Study: NCT05943769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical microsurgery
Description: inoculation of the periapical or the periradicular lesion with the sectioning of the apical 3mm of the root followed by root-end cavity preparation and retro-filling with the MTA or TotalFill with or without composite bone grafting according to patient allocation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical microsurgery
Description: inoculation of the periapical or the periradicular lesion with the sectioning of the apical 3mm of the root followed by root-end cavity preparation and retro-filling with the MTA or TotalFill with or without composite bone grafting according to patient allocation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical microsurgery
Description: inoculation of the periapical or the periradicular lesion with the sectioning of the apical 3mm of the root followed by root-end cavity preparation and retro-filling with the MTA or TotalFill with or without composite bone grafting according to patient allocation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical microsurgery
Description: inoculation of the periapical or the periradicular lesion with the sectioning of the apical 3mm of the root followed by root-end cavity preparation and retro-filling with the MTA or TotalFill with or without composite bone grafting according to patient allocation.
Study: NCT04074590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS006
Description: capsule for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule for oral use
Study: NCT00681616

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Compartment Monitoring System (CMS)
Description: The CMS consists of an Introducer, Pressure Measurement \& Fluid Collection (PMFC) catheter, a Fluid Collection (FC) catheter and Compartment Pressure Monitor. The PMFC catheter removes fluid and monitors pressure via a solid-state fiber optic transducer at the tip of the catheter. The FC catheter only removes fluid and does not have a pressure transducer at the tip. The CMS Monitor senses, displays and records compartment pressure as measured by up to two PMFC catheters. In addition, the CMS Monitor measures subject blood pressure using a provided cuff for calculating the perfusion pressure of the muscle compartment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compartment Monitoring System (CMS)
Description: The CMS consists of an Introducer, Pressure Measurement \& Fluid Collection (PMFC) catheter, a Fluid Collection (FC) catheter and Compartment Pressure Monitor. The PMFC catheter removes fluid and monitors pressure via a solid-state fiber optic transducer at the tip of the catheter. The FC catheter only removes fluid and does not have a pressure transducer at the tip. The CMS Monitor senses, displays and records compartment pressure as measured by up to two PMFC catheters. In addition, the CMS Monitor measures subject blood pressure using a provided cuff for calculating the perfusion pressure of the muscle compartment.
Study: NCT00681616

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Compartment Monitoring System with Active Fluid Removal
Description: Compartment Monitoring System with Active Fluid Removal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compartment Monitoring System without fluid removal
Description: Compartment Monitoring System without fluid removal
Study: NCT03299686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJM112
Description: 300 mg CJM112 (Study treatment) s.c. injection received per week for the first 4 weeks, followed by once every two weeks up to Week 12 (Day 85) + standard of care treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to CJM112
Description: Placebo to match CJM112 + standard of care treatment
Study: NCT00544115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study: NCT02769234

Intervention type: PROCEDURE
Intervention: ERP/EEG test
Description: The testing protocol consists of an auditory oddball ERP paradigm, followed by the collection of 3min of resting EEG. During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 3 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 45-60 minutes.

Intervention type: PROCEDURE
Intervention: Psychometric testing
Description: Subjects that complete ERP/qEEG testing successfully will move on to clinical and neuropsychological evaluation. Demographic information with also be collected.
Study: NCT01092403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASM-024
Description: ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily by inhalation
Study: NCT01960725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV5 (Pentavalent Rotavirus Vaccine)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RV5 (Pentavalent Rotavirus Vaccine)
Study: NCT02403882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order
Description: In the order intervention, the investigators place the targeted product at the front of the line for the treatment. For the control, the investigators place the targeted product at the end of the line.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Packaging
Description: In the packaging intervention, the investigator present the targeted product in the original package. In the control, the investigator repackage the targeted product in clear, plastic bags.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pricing
Description: In the pricing intervention, the investigators price all or targeted products in the treatment. In the control, the investigators do not price the products.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relative Proportions
Description: The investigators adjust the amount of the targeted good available relative to the other products. In the treatment, the targeted good is a larger proportion of the total goods offered in the section, while in the control the shares of the targeted and other goods are equal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Option
Description: In an early site, the investigators offer a targeted product without an alternative. The subjects can accept or reject the offer. The subjects are told that an alternative product is available later. At the site where the alternative product is available, investigators offer subjects the opportunity to exchanged the targeted product for the alternative product.
Study: NCT00079911

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: valacyclovir hydrochloride
Description: valacyclovir hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir hydrochloride
Description: valacyclovir hydrochloride
Study: NCT02524301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography using [11C]diprenorphine
Description: PET using \[11C\]diprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography using [11C]diprenorphine
Description: PET using \[11C\]diprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography using [11C]diprenorphine
Description: PET using \[11C\]diprenorphine
Study: NCT01250535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 10 mg, po, single dose on day 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Warfarin
Description: 10 mg, po, single dose on day 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po, once a day, days 1 through 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: 40 mg, po, once a day, days 1 through 14
Study: NCT03138733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole medocaril
Description: Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril) as a 2 h infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam
Study: NCT01830088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment Based Family Therapy
Description: Attachment-Based Family Therapy (ABFT) is is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
Study: NCT01291537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duodopa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: best médical treatment
Study: NCT01064908

Intervention type: DEVICE
Intervention: OxyMask
Description: Novel vortex oxygen delivery mask
Study: NCT01460498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Description: Starting Dose 50 mg/m2 by subcutaneous or by vein for 3 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor (TKI)
Description: Continuation of dose already receiving during previous 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor (TKI)
Description: Continuation of dose already receiving during previous 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2 daily for 3 days, unless MTD defined at lower dose level in Phase I then that would become dose used for Phase II.
Study: NCT03321825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero® Volume Lidocaine
Description: Mode of application: subdermal injection
Study: NCT03716817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetric CAD
Description: Resilient ceramic crowns (Tetric CAD by Ivoclar Vivadent) are placed using an adhesive bonding process including a total etch process with a universal adhesive (Adhese by Ivoclar Vivadent) and dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
Study: NCT02361125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue. Participants to take a maximum of 20 mg/day, for total of 28 tablets for 7 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue Evaluations
Description: Participants to have evaluation of their fatigue, ability to sleep, and will answer a set of general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment.
Study: NCT00021814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxazosin placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finasteride placebo
Study: NCT00914277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR407899
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR407899
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR407899
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR407899
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral administration
Study: NCT01406171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral
Study: NCT01763346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 1000 mg bid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gastric banding
Description: LAP-BAND
Study: NCT03959930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal Fluid Removal
Description: The Transdermal Fluid Removal (TFR) device is designed for use on the lower limbs of patients with Chronic Heart Failure and treatment resistant peripheral oedema.~The TFR device is intended to be applied on oedematous skin of eligible patients, for periods of up to 10 hours at a time, to gently remove excess fluid through the skin, over a period of a few days during exacerbations, thereby avoiding hospitalisation for intravenous diuretics.~The TFR device is designed to be used in conjunction with standard Negative Pressure Wound Therapy (NPWT) devices which are currently CE Marked and approved for use in both acute and homecare environment.
Study: NCT01214499

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transmyocardial revascularization (TMR) with Holmium YAG laser
Description: Transmyocardial revascularization (TMR) is a surgical procedure that uses a laser to create channels through the myocardial, so this laser stimulates local angiogenesis and provides blood in the ischemic area.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.
Description: The system called PHOENIXTM consists of a laser probe with Holmium:YAG energy capable of creating transmural channels in the myocardium. Surrounding this fibre 3 needles with side holes are arranged so that the implantation of stem cells is done on the edges of the channel and not on the channel itself. This device is capable of distributing stem cells in those channels created by the laser, carrying out both procedures simultaneously.
Study: NCT05129371

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercise
Description: Following the protocol prepared, the breathing exercise group is given breathing exercises for about 20 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application. Reminders (by text message or voice call) are used for the remaining 4 days of the week, allowing the patient to do it on their own.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Breathing Group
Description: The placebo group is asked to breathe normally through the nose with eyes closed, sitting in the same position as the intervention group for 10-15 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application.
Study: NCT00809783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: Tanezumab 10 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: Tanezumab 5 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: Tanezumab 2.5 mg
Study: NCT01847599

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib
Study: NCT00571766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: Oral L-Arginine 2g, twice a day for 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 g twice a day for 14 weeks
Study: NCT04345159

Intervention type: OTHER
Intervention: Questionnaire by phone call
Description: 2 questionnaires : at inclusion and 4 months later. The exposure to hydroxychloroquine and the history of autoimmune disease is determined during the phone call along with other exposure factors. The symptoms presented by the patient are classified in Suggestive of a COVID-19 infection or Not suggestive of COVID-19 infection by a team of internists and infectious diseases specialists, by studying the questionnaires after the completion in a blind-manner regarding the hydroxychloroquine intake.
Study: NCT01446796

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)
Description: Pacing parameters set to AAI 90

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)
Description: Pacing parameters set to DDD 90-100
Study: NCT04193839

Intervention type: OTHER
Intervention: Computerized Provider Order Entry (CPOE) plus Bar Code Medication Administration (BCMA)
Description: Computerized provider order entry (CPOE) refers to the process of providers entering and sending treatment instructions - including medication, laboratory, and radiology orders - via a computer application rather than paper, fax, or telephone. The bar Code Medication Administration (BCMA) is a system that consists of a bar code reader, a portable or desktop computer with wireless connection, a computer server, and some software. Before the administration of medications to the patients the patient unique barcode identification is scanned in order to verify the patient's identity.
Study: NCT00483834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg, IV, day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 200mg/m\^2, IV, day 1 each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m\^2 or 750mg/m\^2 for patients over 65yrs old PO BID, day 1-14 each cycle
Study: NCT03131960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired Vagus Nerve Stimulation
Description: Stimulation of the vagus nerve that is paired with upper limb rehabilitation movements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation movements to improve upper limb function after stroke

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation movements to improve upper limb function after stroke
Study: NCT04712786

Intervention type: OTHER
Intervention: pars plana vitrectomy
Description: 23 gauge pars plana vitrectomy was performed for retinal detachment, vitreous hemorrhage or epiretinal membrane
Study: NCT02336113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary treatment
Description: The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug information (written and oral) to the patient before discharge, as well as written drug information to the next level of care
Study: NCT04798508

Intervention type: OTHER
Group type: OTHER
Intervention: Evoked related potential - P3 paradigm
Description: Evoked related potential are performed for each patient during listen to its own name uttered by i) a neutral voice ii) a smiling voice iii) a rough voice
Study: NCT05087797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicorandil
Description: Patients in the nicorandil group were also given nicorandil (Tohoku Nipro Pharmaceutical Corporation, Japan) orally 5 mg three times per day for 3 months
Study: NCT01367613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone
Study: NCT03327051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Proton pump inhibitor (PPI) that suppresses gastric acid secretion

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL #3
Description: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: VSL #3
Description: Probiotics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match omeprazole